In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Secure dosing routine. Supplemental participants will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, https://is-abbv-744-effective-for68013.life3dblog.com/31141179/abbv-744-cancer-treatment-clinical-trials-an-overview